Taysha Gene Therapies, Inc.NASDAQ: TSHA

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

· Issued by Taysha Gene Therapies, Inc.

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to

Taysha Gene Therapies, Inc. on 6ix

Earlier from Taysha Gene Therapies

Later from Taysha Gene Therapies

All Taysha Gene Therapies news releases